Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Upper Respiratory Drugs: First and Second-Generation Antihistamines01:15

Upper Respiratory Drugs: First and Second-Generation Antihistamines

Antihistamines are a class of drugs widely used to alleviate the symptoms of allergies, such as sneezing, itching, and nasal congestion. They work by inhibiting the actions of histamine, which is released by immune cells in response to allergenic substances or tissue injuries.
Histamine binds to specific receptor sites, known as H1 receptors, on tissue cells, triggering inflammation and swelling. Antihistamines combat these effects by competing with histamine for these receptor sites. By...
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Off-label testosterone therapy is associated with higher long-term cardiovascular risk in men.

EBioMedicine·2026
Same author

Standardizing Prurigo Control Assessment Globally: Linguistic Validation and Cross-cultural Adaptation of Prurigo Control Test in 18 Languages.

Acta dermato-venereologica·2026
Same author

Psychiatric Risk in Chronic Spontaneous Urticaria: A Retrospective Cohort Study.

Acta dermato-venereologica·2026
Same author

A Real-World Cross-Sectional Study on Suspected Mast Cell Activation Syndrome: Multiple Heterogeneous Symptoms Identified.

Clinical and translational allergy·2026
Same author

Urticaria: A debilitating disorder with emerging therapies.

Trends in molecular medicine·2026
Same author

Further Validation and Threshold Determination of Brazilian-Portuguese Version of the CU-Q2oL Questionnaire.

The British journal of dermatology·2026

Related Experiment Videos

Second-Generation H1-Antihistamines Do Not Alter Dementia Risk in Type 2 Inflammatory Diseases: A Target Trial

Henning Olbrich1, Pavel Kolkhir2, Torsten Zuberbier3

  • 1Department of Dermatology, University Hospital Schleswig-Holstein (UKSH), Campus Lübeck, Lübeck, Germany.

The Journal of Allergy and Clinical Immunology. in Practice
|June 6, 2026
PubMed
Summary
This summary is machine-generated.

Second-generation H1-antihistamines (sgAH) used for chronic inflammatory diseases like chronic urticaria do not increase dementia risk. This study found no link between sgAH use and dementia, suggesting potential benefits from alternative treatments.

Keywords:
Allergic rhinitisChronic sinusitisCorticosteroidsDementiaFirst-generation H1-antihistaminesReal-world evidenceSecond-generation H1-antihistaminesTarget trial emulationTriNetXchronic urticaria

Related Experiment Videos

Area of Science:

  • Pharmacology and Geriatric Medicine
  • Epidemiology and Public Health

Background:

  • Second-generation H1-antihistamines (sgAH) are common treatments for type 2 chronic inflammatory diseases such as chronic urticaria (CU), chronic sinusitis (CS), and allergic rhinitis (AR).
  • Existing safety data for sgAH do not fully address potential long-term risks, including dementia.

Purpose of the Study:

  • To investigate the association between second-generation H1-antihistamine use and the risk of developing dementia in patients diagnosed with CU, CS, or AR.
  • To compare dementia risk among users of sgAH, first-generation H1-antihistamines (fgAH), and non-antihistamine alternatives.

Main Methods:

  • A target trial emulation study utilizing real-world data from the TriNetX electronic health record network.
  • Inclusion criteria: patients aged 50 years or older with CU, CS, or AR and no prior dementia diagnosis.
  • Propensity-score matching was used to compare dementia incidence over 5 years between treatment groups (sgAH, fgAH, steroids).

Main Results:

  • Analysis included over 48,000 patients with CU, 21,000 with CS, and 36,000 with AR, matched with control groups.
  • No increased dementia risk was found for users of sgAH or fgAH compared to non-antihistamine controls.
  • Intranasal steroid use in allergic rhinitis patients showed a slight decrease in dementia risk (p=0.007).

Conclusions:

  • Current evidence does not support an increased risk of dementia associated with the use of second-generation H1-antihistamines.
  • Observed lower dementia rates in some patient groups may be attributed to the therapeutic effects of alternative treatments, such as corticosteroids, rather than adverse effects of sgAH.